Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsTargeted therapy for advanced renal cell carcinomaA comprehensive overview of targeted therapy in metastatic renal cell carcinomaAxitinib for the management of metastatic renal cell carcinomaAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesAxitinib in Metastatic Renal Cell CarcinomaEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkersA Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Magnetic resonance imaging and computed tomography characteristics of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialThe association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsTargeted therapies in renal cell cancer: recent developments in imagingPhase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Sunitinib and other targeted therapies for renal cell carcinoma.Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmImmunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Future directions in renal cell carcinoma: 2011 and beyondTargeting the tumor microenvironment: focus on angiogenesis.Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsVEGF spliced variants: possible role of anti-angiogenesis therapy.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.Sunitinib re-challenge in advanced renal-cell carcinoma.
P2860
Q21183974-2895CE6F-5BE9-451F-B212-0DA60F27ADA0Q24242946-C8D60322-0CD0-478A-B373-8759DBB1D2ACQ24606852-3066D706-41BA-4D5D-9CD6-2C3DF2AFBA90Q24613720-28DB72C4-F945-49FD-AE1A-A488FC2991D9Q26751341-461F4CB2-5FF6-41AE-B466-49FF1C7CFF75Q26852437-D65415D5-8C6C-4F8C-8080-EECD45BC5A22Q26998017-80D833A9-9E9A-43F9-8888-3AD9CD3B52ECQ27028048-DDC0B502-AFB3-4292-97A6-7BD4007F8A60Q28765488-2C440699-6B49-4539-B2B1-19A2082CC7C2Q30250106-349CC171-CA2F-4DA3-B9D8-ECAFC11B2EF8Q30472042-F9333E0D-83B9-47F1-B77F-F959F8C631F4Q31131055-2712DF61-0BA7-4484-BB1B-8D4A7C90F7C6Q33398485-70EFD999-FA0A-4610-9D0E-F649DC7E7C0BQ33424379-E3CE8523-1B06-4CCE-A9B1-F9BD0F60FAB6Q33633424-41A41992-D892-49E9-A2FA-F311E7433741Q33754360-E03F8C00-2A13-4294-9652-5A5318B177DEQ33770680-70D2E6B1-2BF3-4A28-A4C2-768F94E3AEC2Q33895119-FAF525DF-D085-4930-992F-A848121622B0Q33985467-99D2AA8C-4288-4E2A-8659-0C57E15FF7BDQ33997879-BCB53CDA-7925-42B5-8837-A8D96CE3ECE1Q34086952-0D1D293B-DB1E-4E83-ACBA-9633419554C8Q34088696-BF008C3B-8974-4C77-BC97-D14CC73C11EEQ34206601-7F812284-638E-4E6A-BF6E-1A8F4324D728Q34245458-084E3998-77E3-4CAD-81E9-6131BAA9C101Q34554398-26200353-6CEC-4C6B-9EE6-143E2EA096A6Q34616440-5D13C18B-14C2-4BF1-95A7-B4D6078762ECQ34621802-95CF84C8-47C6-4659-B276-C00EACF7AB37Q34627163-E1BEDFD5-1CF8-484B-AB91-99ED252A9177Q34636002-523004C8-76D4-4B9A-A398-82C47D6A5B8AQ34660154-C59EF7E0-FC5F-4DF3-A5DF-7B867B77228EQ34661185-914967B4-27A8-4629-B93C-C621FC002EE4Q35152107-30397B82-3E47-4918-A1F0-7E1457CA8576Q35184806-1074A917-78E9-49CB-B724-AABEA7AE8C10Q35209594-9A7C83AF-BD3F-419F-9DAF-A72A1E4E5CA9Q35369677-ADA9AD92-DC84-460D-843D-AADFF45C0946Q35413876-5E931493-6E6A-4240-AC10-584B799185DEQ35562209-AC07E845-4053-49D3-9E2D-B75442D1D422Q35667342-2C26E35F-694C-4A78-8905-718A3EE936C4Q35672426-DB0E75BA-7342-4CF4-A074-1FF8436C5FF4Q35678358-A1C9947A-57B3-4629-922F-7AF50151DE67
P2860
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@en
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@nl
type
label
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@en
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@nl
prefLabel
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@en
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@nl
P2093
P356
P1476
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
@en
P2093
Brad Rosbrook
Brian I Rini
Gary Hudes
Jamal Tarazi
Janice P Dutcher
Laura Wood
Peter C Trask
Walter M Stadler
P304
P356
10.1200/JCO.2008.21.7034
P407
P577
2009-08-03T00:00:00Z